Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
Explore the impact of the first-line application of Toripalimab with or without Lenvatinib or chemotherapy, on the survival, disease progression, and drug safety of patients with advanced biliary tract cancers
Biliary Tract Neoplasms Immunotherapy
DRUG: Toripalimab|DRUG: Lenvatinib|DRUG: Gemox Chemotherapy（Gemox or GC）
Objective response rate (ORR), Objective response rate, Baseline up to approximately 6 months
Disease control rate (DCR), DCR refers to the proportion of patients whose tumor volume control (shrinkage or enlargement) reaches a predetermined value and can maintain the minimum required duration. According to the RECIST criteria (version 1.1), during the treatment period or within 30 days after the discontinuation of the investigational drug, it is the sum of the percentage of subjects who achieve complete response (CR), partial response (PR), and stable disease (SD), Baseline up to approximately 6 months|Progression-free survival (PFS), It refers to the time from the first administration of the regimen to the first occurrence of disease progression or death due to any cause in the subjects., Baseline up to approximately 12 months|Overall survival, The time from randomization to death due to any cause in the subjects, Baseline up to approximately 12 months|Duration of response, It refers to the time from the first report of objective tumor partial or complete response (based on the earlier occurrence) to the first occurrence of disease progression or death in the subjects, Baseline up to approximately 12 months|Clinical benefit rate, The ratio of subjects who achieve complete response (CR) or partial response (PR) or maintain stable disease (SD) ., Baseline up to approximately 12 months
Explore the impact of the first-line application of Toripalimab with or without Lenvatinib or chemotherapy, on the survival, disease progression, and drug safety of patients with advanced biliary tract cancers